DENTSPLY SIRONA heads into today's Q1 print with options traders and short sellers both leaning negative — and a fresh initiation from Citi pulling targets toward the downside.
Options positioning has become notably more defensive in recent weeks. The put/call ratio has climbed to 0.96, running well above its 20-day average of 0.74 — about 1.4 standard deviations above the norm. That shift is visible in the history: the PCR spent most of March and early April below 0.62, then ratcheted steadily higher through late April as the print approached. Defensive hedging has clearly picked up pace, even if the ratio hasn't reached its 52-week high of 1.21.
Short interest reinforces that cautious tone. At roughly 10% of free float, it is a material position. The level rose about 8.5% over the past month — driven largely by a step-change in mid-April — and has only eased slightly in the past week. With days to cover near 7 and borrowing costs remaining low at 0.37% (down sharply from above 0.50% for most of April), the lending market is not yet flashing squeeze pressure. Availability remains ample, suggesting new shorts face little friction if sentiment deteriorates further.
The analyst debate captures the fork the stock faces. Citigroup initiated with a Sell and a $10 target on April 15, citing the lack of evidence that any operational improvement is materialising — a view aligned with the bear case that executive turnover, a reduced FY26 profitability outlook, and repeated failed turnaround plans make this a show-me story. The bull case points to Q4's better-than-expected top-line result, the restructuring plan gaining traction, and management's decision to eliminate the dividend in order to pay down debt and buy back shares. Several firms raised targets in late February following the Q4 print — Mizuho, Barrington, Wells Fargo and Evercore all lifted numbers then. But the stock has since given back much of that rally: down 3.7% over the past month and off 6.4% on the week, now trading at $11.20, below all but the Citi target. A P/E below 8x and EV/EBITDA near 7.3x reflect the market's hesitation rather than conviction either way.
One ownership note is worth flagging. Southpoint Capital reported a fresh 10 million-share position as recently as March 11 — a new entry that ranks it fifth among all holders. That is a meaningful vote of confidence from a known active manager, though the Chairman's own March 9 open-market purchase of 15,000 shares at $12.45 now sits underwater. Historical reactions have been volatile: the stock fell 9.4% over the day following the December print, then surged 14.7% after February's Q4 numbers — the range is wide in both directions.
Today's print is a test of whether the February optimism was justified or premature: specifically, whether revenue trends have held up, margin guidance for the full year can be maintained, and the new leadership can offer enough evidence of operational stability to close the gap between the Citi bear case and the $16–17 targets still held by the remaining bulls.
See the live data behind this article on ORTEX.
Open XRAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
